evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

471 questions · 478 findings · 111 reviews

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 68 · 14.2%GRADE not reported 42 · 8.8%Very low 143 · 29.9%Low 133 · 27.8%Moderate 73 · 15.3%High 19 · 4%

Immune checkpoint inhibitors vs any second‐line chemotherapy

Discontinuation of medication due to adverse events · participants with advanced or metastatic muscle invasive bladder cancer

Immune checkpoint inhibitors may leads to lower discontinuation due to adverse events Range of compared with any second‐line chemotherapy (low certainty).

1 finding from 1 review

Immune checkpoint inhibitors vs any first‐line chemotherapy

Discontinuation of medication due to adverse events · participants with advanced or metastatic muscle invasive bladder cancer

Immune checkpoint inhibitors showed no clear difference in discontinuation due to adverse events Range of compared with any first‐line chemotherapy (low certainty).

1 finding from 1 review

Intervention not reported

Time to initiation of first subsequent therapy This outcome was not reported as a time‐to‐event outcome. Instead, authors of the trials reported the number of participants who received subsequent anticancer therapy after discontinuation of trial t... · people with a confirmed diagnosis of advanced renal cell carcinoma (combined risk groups) without previous systemic anticancer therapy

The intervention may leads to lower time to initiation of first subsequent therapy This outcome was not… (low certainty).

1 finding from 1 review

Intervention not reported

Discontinuation of study drug due to adverse events · unvaccinated, non‐hospitalized people with mild symptomatic COVID‐19 (WHO scale 2 to 3) at high risk for progression to severe disease

The intervention probably leads to lower discontinuation of study drug due to adverse events (moderate certainty).

1 finding from 1 review

Intervention not reported

Discontinuation of study drug due to adverse events · hospitalized people with mild to moderate symptomatic COVID‐19 (WHO scale 2 to 4) with severe comorbidities

The review found no eligible studies for this question.

1 finding from 1 review

NSAIDs vs placebo

Persistence of visual improvement one month after discontinuation of treatment · participants with chronic CME (≥ 4 months) following cataract surgery

It is very uncertain whether NSAID changes persistence of visual improvement one month after discontinuation of… compared with placebo (very low certainty).

1 finding from 1 review

Mepolizumab intravenous (IV) vs placebo

Clinically significant adverse events leading to discontinuation · people with asthma

Mepolizumab intravenous (IV) showed no clear difference in clinically significant adverse events leading to discontinuation compared with placebo (high certainty).

1 finding from 1 review

Reslizumab intravenous (IV) vs placebo

Clinically significant adverse events leading to discontinuation · people with asthma

Reslizumab intravenous (IV) showed no clear difference in clinically significant adverse events leading to discontinuation compared with placebo (high certainty).

1 finding from 1 review

Reslizumab subcutaneous (SC) vs placebo

Clinically significant adverse events leading to discontinuation · people with asthma

Reslizumab subcutaneous (SC) showed no clear difference in clinically significant adverse events leading to discontinuation compared with placebo (moderate certainty).

1 finding from 1 review

Benralizumab subcutaneous (SC) vs placebo

Clinically significant adverse events leading to discontinuation · people with asthma

Benralizumab subcutaneous (SC) leads to higher clinically significant adverse events leading to discontinuation compared with placebo (high certainty).

1 finding from 1 review

Mepolizumab subcutaneous (SC) vs placebo

Clinically significant adverse events leading to discontinuation · people with asthma

Mepolizumab subcutaneous (SC) showed no clear difference in clinically significant adverse events leading to discontinuation compared with placebo (high certainty).

1 finding from 1 review

Clonazepam vs carbamazepine

Proportion of participants with treatment‐emergent adverse events (TEAEs) ‐ Leading to discontinuation during the treatment period № of participants: 36 (1 RCT) · people with newly diagnosed epilepsy

It is very uncertain whether clonazepam changes proportion of participants with treatment‐emergent adverse events… compared with carbamazepine (very low certainty).

1 finding from 1 review

Etanercept vs no etanercept

Adverse effects leading to discontinuation of SJT/TEN therapy ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome

The review found no eligible studies for this question.

1 finding from 1 review

Cyclosporin vs no cyclosporin

Adverse effects leading to discontinuation of SJT/TEN therapy ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome

The review found no eligible studies for this question.

1 finding from 1 review